Innovations In Clinical Neuroscience

SEP-OCT 2014

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 199 of 201

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 1 , N U M B E R 9 – 1 0 , S E P T E M B E R – O C T O B E R 2 0 1 4 ] 200 R E S E A R C H T O P R A C T I C E 3. Mills PD, Watts BV, DeRosier JM, et al. Suicide attempts and completions in the emergency department in Veterans Affairs hospitals. Emergency Med J. 2012;29(5):399–403. 4. Canapary D, Bongar B, Cleary K. Assessing risk for completed suicide in patients with alcohol dependence: clinicians' views of clinical factors. Professional Psychology: Research and Practice. 2002;33(5):464–469. 5. Mitchell AM, Garand L, Dean D, et al. Suicide assessment in hospital emergency departments: implications for patient satisfaction and compliance Top Emerg Med. 2005;27(4):302–312. 6. Larkin GL, Smith RP, Beautrais AL. Trends in US emergency department visits for suicide attempts, 1992-2001. Crisis. 2008;29(2):73–80. 7. King CA, O'Mara RM, Hayward CN, Cunningham RM. Adolescent suicide risk screening in the emergency department. Acad Emerg Med. 2009;16(11):1234–1241. 8. Larkin GL, Beautrais AL, Spirito A, et al. Mental health and emergency medicine: a research agenda. Acad Emerg Med. 2009;16(11):1110–1119. 9. American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry. 2003;160(11 Suppl):1–60. 10. Substance Abuse and Mental Health Services Administration. After an Attempt: A Guide for Medical Providers in the Emergency Department Taking Care of Suicide Attempt Survivors. DHHS Pub. No. (SMA) 08-4359, Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, 2006. Reprinted by the Department of Veterans Affairs, Veterans Health Administration, 2008. FUNDING: There was no funding for the development and writing of this article. AUTHOR AFFILATIONS: Steven D. Targum, MD, is the scientific director at Clintara LLC, the chief medical officer at Methylation Sciences Inc., BrainCells Inc., and Functional Neuromodulation Inc., the chief medical advisor at Prana Biotechnology Ltd., and a consultant in psychiatry at the Massachusetts General Hospital, Boston, Massachusetts. Dr. Frank Friedman is an Assistant Professor of Emergency Medicine at Tufts University School of Medicine and the Director of Prehospital Care and Emergency Preparedness at Tufts Medical Center in Boston, Massachusetts. Dr. Manuel N. Pacheco is an Assistant Professor of Psychiatry at Tufts University School of Medicine and Chief of the Consultation/Liaison Service and of the Emergency Service, Department of Psychiatry at the Tufts Medical Center in Boston, Massachusetts. FINANCIAL DISCLOSURES: Dr. Targum has received consultation fees, retainers, or vendor grants from the following sponsors within the past three years: Acadia Pharmaceuticals, Acumen, Alcobra, Alkermes Inc., AstraZeneca, BioMarin, BrainCells Inc., Civitas, Eli Lilly and Company, EnVivo (Forum) Pharmaceuticals, Euthymics, Functional Neuromodulation Inc, Intracellular Therapies Inc., Ironwood Pharmaceuticals, Johnson & Johnson PRD, Methylation Sciences Inc., Mitsubishi Tanabe, NeoSync, Novartis Pharmaceuticals, Nupathe, Pfizer Inc., Prana Biotechnology Ltd., ReViva, Roche Labs, Sophiris, Sunovion, Targacept, Theravance, Transcept. Drs. Friedman and Pacheco have no conflicts of interests related to the writing of this paper. ADDRESS CORRESPONDENCE TO: Dr. Steve Targum, 505 Tremont St., #907, Boston, MA 02116; E-mail:

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - SEP-OCT 2014